Pharm Exec's Pipeline Report 2018
The market for anti-smoking products exceeds $2 billion, but their superiority over cold-turkey quitting remains controversial. The first vaccines are set to offer a new weapon in the fight against nicotine addiction. Long-lasting single injections, these new vaccines remove the hurdle of daily adherence while sparking the immune system to produce nicotine-specific antibodies that aggregate nicotine in the bloodstream, resulting in a nicotine complex too large to cross the blood-brain barrier where the reward system awaits. Denying the pleasure of the fix may indirectly help minimize the craving that accompanies quitting smoking. Although Nabi Biopharma/GSK's NicVAX is on schedule to beat Novartis' NIC-002 to market, the Swiss firm's vax is expected to grab a larger market share because of its greater efficacy—and Novartis' marketing muscle, says Datamonitor's Ben Greenacre.
Cell and Gene Therapy Check-in 2024
January 18th 2024Fran Gregory, VP of Emerging Therapies, Cardinal Health discusses her career, how both CAR-T therapies and personalization have been gaining momentum and what kind of progress we expect to see from them, some of the biggest hurdles facing their section of the industry, the importance of patient advocacy and so much more.